Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. A, 43-48
© 1999 The British Society for Antimicrobial Chemotherapy
Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose
a The Clinical Pharmacokinetics Laboratory, Millard Fillmore Health System, 3 Gates Circle, Buffalo, NY 14209; b Bayer Corporation, Pharmaceutical Division, West Haven, CT, USA
Intravenous ciprofloxacin is frequently prescribed for the treatment of infections due to nosocomially acquired Gram-negative organisms, including those originating in the respiratory tract. In this study, the concentrations of ciprofloxacin in serum and lung tissue were determined by HPLC in patients undergoing lung surgery. A total of 22 patients scheduled for lung surgery received a single 400 mg iv dose of ciprofloxacin administered as a 1 h infusion. A specimen of healthy lung tissue was obtained from resected lung from 18 of the patients for analysis of ciprofloxacin concentration during the following time intervals after infusion (one sample/patient): 0- 2, 2- 4, 4- 8 and 8- 12 h. Corresponding mean serum and tissue concentrations were 2.37 mg/L and 3.84 mg/kg (0- 2 h), 1.18 mg/L and 1.92 mg/kg (2- 4 h), 0.69 mg/L and 1.77 mg/kg (4- 8 h), and 0.13 mg/L and 0.67 mg/kg (8- 12 h). Ciprofloxacin distributed rapidly to lung tissue, as seen by the high concentrations in the lung tissue as early as 2 h after infusion. Concentrations in lung tissue were generally higher than those in serum (tissue:serum ratios ranged from 1.7 to 7.1). The mean tissue concentrations found in this study remained above the MIC for most susceptible organisms.
* Tel: +1-716-887-5163; Fax: +1-716-887-4566.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Grayo, M.-C. Lott-Desroches, O. Dussurget, R. Respaud, A. Fontanet, O. Join-Lambert, E. Singlas, and A. Le Monnier Rapid Eradication of Listeria monocytogenes by Moxifloxacin in a Murine Model of Central Nervous System Listeriosis Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3210 - 3215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dupont, D. Hocquet, K. Jeannot, P. Chavanet, and P. Plesiat Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa J. Antimicrob. Chemother., April 1, 2005; 55(4): 518 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Rodriguez, L. Cebrian, M. Lopez, M. Ruiz, I. Jimenez, and G. Royo Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis J. Antimicrob. Chemother., March 1, 2004; 53(3): 441 - 444. [Abstract] [Full Text] [PDF]
|
|